Key statistics dashboard for REGENXBIO Inc. (RGNX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system.
Stock Data
| Price | $7.98 |
| Market Cap | $413M |
| Enterprise Value | $445.0M |
| Beta | 1.13 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.11 |
| Price / Book | 5.87 |
| P/S | 2.36 |
| EV/EBITDA | -3.20 |
| EV/Sales | 2.55 |
| EV/FCF | -1.78 |
| P/FCF | -1.65 |
| Earnings Yield | -46.60% |
| FCF Yield | -60.52% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 54.22% |
| EBIT Margin | -88.54% |
| EBITDA Margin | -79.73% |
| Operating Margin | -94.08% |
| Net Margin | -112.58% |
| Return on Equity | -220.07% |
| Return on Assets | -50.81% |
| Return on Invested Capital | -52.72% |
| Return on Capital Employed | -54.00% |
Financial Health
| Current Ratio | 2.86 |
| Quick Ratio | 2.86 |
| Cash Ratio | 0.44 |
| Debt / Equity | 0.96 |
| Debt / Assets | 17.83% |
| Net Debt / EBITDA | -0.23 |
| Interest Coverage | -3.91 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.57 |
Per-Share Data
| Revenue per share | 3.30 |
| Book Value per share | 1.36 |
| Cash per share | 2.00 |
| FCF per share | -4.73 |
| Tangible Book Value per share | 1.36 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 1 |
| Buy | 13 |
| Hold | 5 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 20 |
| Avg rating (1-5) | 0.70 |
Related companies: ABSI · CRVS · FDMT · GOSS · KALV · MLTX · OLMA
Explore sector: Healthcare · Biotechnology
More sections of RGNX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks